Table 1 Clinicopathological features of 719 cT1 breast cancer patients who underwent surgery without preoperative chemotherapy
From: Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer
Parameters | Number of patients (n = 719) (%) |
|---|---|
Age at operation (years old) | median 58 (range, 29–91) |
Tumor size (mm) | median 13 (range, 3–20) |
Estrogen receptor | |
 Negative / Positive | 107 (14.9%) / 612 (85.1%) |
Progesterone receptor | |
 Negative / Positive | 321 (44.6%) / 398 (55.4%) |
HER2 | |
 Negative / Positive | 653 (90.8%) / 66 (9.2%) |
Ki67 | |
  ≤ 20% / > 20% | 586 (81.5%) / 133 (18.5%) |
Intrinsic subtype | |
 HR + BC / HR-HER2 + BC / TNBC | 621 (86.3%) / 27 (3.8%) / 71 (9.9%) |
Pathological axillary lymph node metastasis | |
 No metastasis / only isolated tumor cell / only micrometastasis / metastasis | 573 (79.7%) / 5 (0.7%) / 29 (4.0%) / 112 (15.6%) |
Lymph vascular invasion | |
 No / Yes | 528 (73.4%) / 191 (26.6%) |
Hyperlipidemia | |
 No / Yes | 572 (79.6%) / 147 (20.4%) |
Number of medicine types for hyperlipidemia | |
 0 / 1 / 2 | 572 (79.6%) / 139 (19.3%) / 8 (1.1%) |
Statins | |
 Non-user / User | 587 (81.6%) / 132 (18.4%) |
Lipophilic statins | |
 Non-user / User | 658 (91.5%) / 61 (8.5%) |
Hydrophilic statins | |
 Non-user / User | 648 (90.1%) / 71 (9.9%) |
Fibrate | |
 Non-user / User | 709 (98.6%) / 10 (1.4%) |
Nicotinic acid (tocopherol acetate) | |
 Non-user / User | 712 (99.0%) / 7 (1.0%) |
Sterol absorption inhibitors (ezetimibe) | |
 Non-user / User | 713 (99.2%) / 6 (0.8%) |